Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion type Assertion NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_head.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion description "[Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic myelogenous leukemia, but the emergence of imatinib resistance underscores the need for additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_provenance.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion evidence source_evidence_literature NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_provenance.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion SIO_000772 15781610 NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_provenance.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion wasDerivedFrom befree-2016 NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_provenance.
- NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_assertion wasGeneratedBy ECO_0000203 NP486376.RAy_TgWuQUpPRdqi_vlB-QkMqKZAnLjkvKV-2iYkEoOHk130_provenance.